{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:53:35Z","timestamp":1794743615864,"version":"4.9.1"},"reference-count":94,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent years have witnessed a rapid growth in our understanding of the pathogenic property of monoclonal proteins. It is evident that some of these small monoclonal proteins are capable of inducing end-organ damage as a result of their intrinsic physicochemical properties. Hence, an umbrella term, monoclonal gammopathy of clinical significance (MGCS), has been coined to include myriad conditions attributed to these pathogenic proteins. Because kidneys are the most commonly affected organ (but skin, peripheral nerves, and heart can also be involved), we discuss MGRS exclusively in this review. Mechanisms of renal damage may involve direct or indirect effects. Renal biopsy is mandatory and demonstration of monoclonal immunoglobulin in kidney, along with the corresponding immunoglobulin in serum or urine, is key to establish the diagnosis. Pitfalls exist at each diagnostic step, and a high degree of clinical suspicion is required to diagnose MGRS. Recognition of MGRS by hematologists and nephrologists is important, because timely clone-directed therapy improves renal outcomes. Autologous stem cell transplant may benefit selected patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019031914","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:45:14Z","timestamp":1565729114000},"page":"2409-2423","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":71,"title":["Pathophysiology and management of monoclonal gammopathy of renal significance"],"prefix":"10.1182","volume":"3","author":[{"given":"Ankur","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[{"name":"Oxford Kidney Unit, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"},{"name":"MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Headington, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"},{"name":"NIHR Biomedical Research Centres Blood Theme, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Khera","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom;"},{"name":"NIHR Biomedical Research Centres Blood Theme, Oxford, United Kingdom;"},{"name":"Oxford Myeloma Centre for Translational Research, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"issue":"12","key":"2020021108183426600_B1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"2020021108183426600_B2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020021108183426600_B3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2215\/CJN.03160316","article-title":"Bridging the divide: an onco-nephrologic approach to the monoclonal gammopathies of renal significance","volume":"11","author":"Hogan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2020021108183426600_B4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/cclm-2015-0994","article-title":"Laboratory testing in monoclonal gammopathy of renal significance (MGRS)","volume":"54","author":"Leung","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"2020021108183426600_B5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s11255-017-1594-y","article-title":"Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity","volume":"49","author":"Ciocchini","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2020021108183426600_B6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2020021108183426600_B7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.5858\/arpa.2013-0493-OA","article-title":"Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis","volume":"138","author":"Herrera","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"2020021108183426600_B8","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020021108183426600_B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"2020021108183426600_B10","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2215\/CJN.02560316","article-title":"Paraprotein-related kidney disease: kidney injury from paraproteins-what determines the site of injury?","volume":"11","author":"Doshi","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2020021108183426600_B11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020021108183426600_B12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"2020021108183426600_B13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2017","journal-title":"Oncotarget"},{"key":"2020021108183426600_B14","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/blood.V124.21.4849.4849","article-title":"Long term survival of monoclonal gammopathy of renal significance (MGRS): an analysis of Nhanes III","volume":"124","author":"Shaik","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2020021108183426600_B15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020021108183426600_B16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2005.05.010","article-title":"Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis","volume":"46","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2020021108183426600_B17","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2020021108183426600_B18","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1046\/j.1523-1755.2002.00628.x","article-title":"Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features","volume":"62","author":"Bridoux","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"2020021108183426600_B19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.10611110","article-title":"Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab","volume":"6","author":"Guiard","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2020021108183426600_B20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/ki.2008.577","article-title":"Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits","volume":"75","author":"Czarnecki","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"2020021108183426600_B21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2020021108183426600_B22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2215\/CJN.05750710","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2020021108183426600_B23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-6143.2012.04326.x","article-title":"Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance","volume":"13","author":"Pinney","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"2020021108183426600_B24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2020021108183426600_B25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2010.1","article-title":"Recurrent membranoproliferative glomerulonephritis after kidney transplantation","volume":"77","author":"Lorenz","year":"2010","journal-title":"Kidney Int"},{"issue":"1","key":"2020021108183426600_B26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"2020021108183426600_B27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"2020021108183426600_B28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"issue":"7","key":"2020021108183426600_B29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2017121319","article-title":"The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases","volume":"29","author":"Sethi","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2020021108183426600_B30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.kint.2016.09.004","article-title":"Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management","volume":"91","author":"Bridoux","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"2020021108183426600_B31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2215\/CJN.00560117","article-title":"Dysproteinemias and glomerular disease","volume":"13","author":"Leung","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2020021108183426600_B32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/labinvest.3700069","article-title":"Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns [published correction appears in Lab Invest. 2004;84(9):1219]","volume":"84","author":"Teng","year":"2004","journal-title":"Lab Invest"},{"issue":"10","key":"2020021108183426600_B33","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/labinvest.3700161","article-title":"AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells","volume":"84","author":"Keeling","year":"2004","journal-title":"Lab Invest"},{"issue":"1","key":"2020021108183426600_B34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5414\/CN108670","article-title":"Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy","volume":"85","author":"Charitaki","year":"2016","journal-title":"Clin Nephrol"},{"issue":"3","key":"2020021108183426600_B35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1092-9134(00)90042-X","article-title":"Renal manifestations of plasma cell dyscrasias: an appraisal from the patients\u2019 bedside to the research laboratory","volume":"4","author":"Herrera","year":"2000","journal-title":"Ann Diagn Pathol"},{"issue":"9","key":"2020021108183426600_B36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0046-8177(94)90007-8","article-title":"Growth factors in monoclonal light-chain--related renal diseases","volume":"25","author":"Herrera","year":"1994","journal-title":"Hum Pathol"},{"issue":"6","key":"2020021108183426600_B37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ekir.2017.07.008","article-title":"Membranous glomerulopathy with light chain-restricted deposits: a clinicopathological analysis of 28 cases","volume":"2","author":"Best Rocha","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2020021108183426600_B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bjh.12398","article-title":"Renal Fanconi syndrome associated with monoclonal \u03ba free light chain in a patient with Waldenstr\u00f6m macroglobulinemia","volume":"162","author":"Ugai","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2020021108183426600_B39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2020021108183426600_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s007950100000","article-title":"The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions","volume":"34","author":"Herrera","year":"2001","journal-title":"Med Electron Microsc"},{"issue":"5","key":"2020021108183426600_B41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2020021108183426600_B42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/modpathol.2011.104","article-title":"The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation","volume":"24","author":"Larsen","year":"2011","journal-title":"Mod Pathol"},{"issue":"4","key":"2020021108183426600_B43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1053\/j.ajkd.2006.01.004","article-title":"Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation","volume":"47","author":"Sanada","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2020021108183426600_B44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.kint.2016.10.043","article-title":"Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias","volume":"91","author":"Lin","year":"2017","journal-title":"Kidney Int"},{"issue":"7","key":"2020021108183426600_B45","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s11255-018-1896-8","article-title":"Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?","volume":"50","author":"Ciocchini","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2020021108183426600_B46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2020021108183426600_B47","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum","volume":"12","author":"Lin","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2020021108183426600_B48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.24745","article-title":"Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia","volume":"92","author":"Sidana","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2020021108183426600_B49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.20643","article-title":"Natural history and therapy of 66 patients with mixed cryoglobulinemia","volume":"81","author":"Bryce","year":"2006","journal-title":"Am J Hematol"},{"issue":"6","key":"2020021108183426600_B50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4103\/0971-4065.151354","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposition disease: the utility of routine staining with immunoglobulin light chains","volume":"25","author":"Gowda","year":"2015","journal-title":"Indian J Nephrol"},{"issue":"11","key":"2020021108183426600_B51","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1093\/ndt\/gfs348","article-title":"Immunotactoid glomerulopathy: clinicopathologic and proteomic study","volume":"27","author":"Nasr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2020021108183426600_B52","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2215\/CJN.08300910","article-title":"Fibrillary glomerulonephritis: a report of 66 cases from a single institution","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2020021108183426600_B53","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int"},{"issue":"12","key":"2020021108183426600_B54","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.2215\/CJN.02980316","article-title":"Paraprotein-related kidney disease: glomerular diseases associated with paraproteinemias","volume":"11","author":"Motwani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2020021108183426600_B55","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V100.5.1817.h81702001817_1817_1827","article-title":"Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature","volume":"100","author":"Lebeau","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2020021108183426600_B56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/leu.2016.195","article-title":"Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients","volume":"31","author":"Vignon","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020021108183426600_B57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype [published correction appears in Kidney Int. 2018;94(5):1025]","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"2020021108183426600_B58","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ckj\/sfw090","article-title":"C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome","volume":"9","author":"Lloyd","year":"2016","journal-title":"Clin Kidney J"},{"issue":"3","key":"2020021108183426600_B59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2020021108183426600_B60","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","article-title":"Dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"56","author":"Sethi","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2020021108183426600_B61","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ajh.24802","article-title":"POEMS syndrome: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Dispenzieri","year":"2017","journal-title":"Am J Hematol"},{"issue":"10038","key":"2020021108183426600_B62","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2020021108183426600_B63","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"2020021108183426600_B64","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020021108183426600_B65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020021108183426600_B66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2014050509","article-title":"Crystalglobulin-induced nephropathy","volume":"26","author":"Gupta","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2020021108183426600_B67","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2215\/CJN.00650110","article-title":"The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies","volume":"5","author":"Fish","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"2020021108183426600_B68","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2020021108183426600_B69","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfh503","article-title":"AL-amyloidosis is underdiagnosed in renal biopsies","volume":"19","author":"Novak","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2020021108183426600_B70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/01913121003672873","article-title":"Ultrastructural immunolabeling in the diagnosis of monoclonal light-and heavy-chain-related renal diseases","volume":"34","author":"Herrera","year":"2010","journal-title":"Ultrastruct Pathol"},{"issue":"1","key":"2020021108183426600_B71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ekir.2017.07.017","article-title":"DNAJB9 is a specific immunohistochemical marker marker for fibrillary glomerulonephritis","volume":"3","author":"Nasr","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"2020021108183426600_B72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.ajkd.2018.03.017","article-title":"Congophilic fibrillary glomerulonephritis: a case series","volume":"72","author":"Alexander","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2020021108183426600_B73","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.ki.5001990","article-title":"Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies","volume":"70","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"issue":"23","key":"2020021108183426600_B74","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021108183426600_B75","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1373\/clinchem.2003.017756","article-title":"Automated multicapillary electrophoresis for analysis of human serum proteins","volume":"49","author":"Gay-Bellile","year":"2003","journal-title":"Clin Chem"},{"issue":"6","key":"2020021108183426600_B76","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","article-title":"Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials","volume":"108","author":"Drayson","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2020021108183426600_B77","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2020021108183426600_B78","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2020021108183426600_B79","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"36","key":"2020021108183426600_B80","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021108183426600_B81","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2020021108183426600_B82","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"issue":"3","key":"2020021108183426600_B83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1797.2005.00387.x","article-title":"Prospects for urinary proteomics: exosomes as a source of urinary biomarkers","volume":"10","author":"Hoorn","year":"2005","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2020021108183426600_B84","doi-asserted-by":"crossref","first-page":"e38061","DOI":"10.1371\/journal.pone.0038061","article-title":"Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)","volume":"7","author":"Ramirez-Alvarado","year":"2012","journal-title":"PLoS One"},{"issue":"17","key":"2020021108183426600_B85","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"issue":"19","key":"2020021108183426600_B86","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"2020021108183426600_B87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2020021108183426600_B88","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021108183426600_B89","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"22","key":"2020021108183426600_B90","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2020021108183426600_B91","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2020021108183426600_B92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"2020021108183426600_B93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000440815","article-title":"end-stage kidney disease due to fibrillary glomerulonephritis and immunotactoid glomerulopathy - outcomes in 66 consecutive ANZDATA Registry cases","volume":"42","author":"Mallett","year":"2015","journal-title":"Am J Nephrol"},{"issue":"1","key":"2020021108183426600_B94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(12)80314-3","article-title":"Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease","volume":"20","author":"Heilman","year":"1992","journal-title":"Am J Kidney Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/15\/2409\/1632500\/advances031914.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/15\/2409\/1632500\/advances031914.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T16:17:59Z","timestamp":1664122679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/15\/2409\/260615\/Pathophysiology-and-management-of-monoclonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":94,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019031914","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]}}}